RxDoctor Payments Data

Kasey Lax

Family · Bolivar, TNNPI 1346565629

Payments from drug & device makers

$196in general payments, 2019–2025

Across 11 payments — averaging $17.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$60
  • Avanir Pharmaceuticals, Inc.$31
  • Otsuka America Pharmaceutical, Inc.$25
  • AbbVie$22
  • GSK$16
  • Lilly USA, LLC$15
  • plus $29 from 2 others

What the payments were for

  • Food & beverage$196100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$196 in reported general payments places this provider in the 35th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$140,420
Medicare patients
255
Services billed
5,655

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide132$148,094
JardianceEmpagliflozin132$119,610
EliquisApixaban100$80,996
Trelegy ElliptaFluticasone/Umeclidin/Vilanter95$72,247
FarxigaDapagliflozin Propanediol79$55,902
TrulicityDulaglutide43$47,560
XareltoRivaroxaban59$42,837
RybelsusSemaglutide37$41,045
JanuviaSitagliptin Phosphate45$39,896
RexultiBrexpiprazole23$32,041
GlyxambiEmpagliflozin/Linagliptin29$27,705
VraylarCariprazine Hcl13$24,109
Tresiba Flextouch U-200Insulin Degludec36$22,223
MyrbetriqMirabegron42$19,548
EntrestoSacubitril/Valsartan21$15,099

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$16$72,24795 claims
AstraZenecaFarxiga$15$55,90279 claims
Lilly USA, LLCTrulicity$15$47,56043 claims
AbbVieVraylar, Linzess$22$35,26830 claims
Otsuka America Pharmaceutical, Inc.Rexulti$25$32,04123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 6,706 family providers in Tennessee.

Other family in Bolivar

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →